CN103768382A - Pharmaceutical composition for preventing and treating left ventricular hypertrophy and application thereof - Google Patents
Pharmaceutical composition for preventing and treating left ventricular hypertrophy and application thereof Download PDFInfo
- Publication number
- CN103768382A CN103768382A CN201410030259.0A CN201410030259A CN103768382A CN 103768382 A CN103768382 A CN 103768382A CN 201410030259 A CN201410030259 A CN 201410030259A CN 103768382 A CN103768382 A CN 103768382A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- left ventricular
- ventricular hypertrophy
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for preventing and treating left ventricular hypertrophy and application of the pharmaceutical composition. The pharmaceutical composition comprises an active component and medical auxiliaries, wherein the active component is prepared from the following traditional Chinese medicinal raw materials in parts by weight: 21-33 parts of lindernia ruellioides, 12-19 parts of leech, 18-26 parts of semen platycladi, 18-26 parts of red rhodobryum, 12-19 parts of codonopsis pilosula, 12-19 parts of astragalus membranaceus, 10-18 parts of radix polygonati officinalis, 30-45 parts of phaseolus calcaratus, 10-18 parts of fructus schizandrae, and 7-13 parts of liquorice. The pharmaceutical composition can be used for synergistically inhibiting formation of left ventricular hypertrophy caused by long-term pressure overload.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of pharmaceutical composition and application thereof that prevents and treats left ventricular hypertrophy.
Background technology
Long-term Pressure Overload-induced is one of major reason causing left ventricular hypertrophy.Myocardium of left ventricle plumpness is the reconstruct of heart generation pathologic, in form, can have myocardial hypertrophy, cardiac weight increase, interstitial fibrosis etc., it be heart to the basic adaptation response of the one of acute and chronic hemodynamics over loading, see multiple cardiovascular disease.Clinical research shows, myocardial hypertrophy is not only a kind of adaptation response before heart failure, and is the independent risk factor of the cardiovascular events such as ischemia, arrhythmia, sudden death.
Summary of the invention
In view of the deficiencies in the prior art, the object of the invention is to carry by a large amount of animal experiments and further investigate, a kind of pharmaceutical composition and application thereof of control left ventricular hypertrophy of evident in efficacy, with low cost, almost non-toxic side effect are provided.
In order to realize object of the present invention, inventor studies by lot of experiments and not at all explores, and has finally obtained following technical scheme:
A kind of pharmaceutical composition of preventing and treating left ventricular hypertrophy, be made up of active component and pharmaceutically acceptable auxiliaries, described active component is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Lindernia ruellioides (Colsm.) Pennell 21-33 part, Hirudo 12-19 part, Semen Platycladi 18-26 part, Rhodobryum roseum Limpr. 18-26 part, Radix Codonopsis 12-19 part, Radix Astragali 12-19 part, Rhizoma Polygonati Odorati 10-18 part, Semen Phaseoli 30-45 part, Fructus Schisandrae Chinensis 10-18 part, Radix Glycyrrhizae 7-13 part.
Preferably, the pharmaceutical composition of control left ventricular hypertrophy as mentioned above, wherein said active component is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Lindernia ruellioides (Colsm.) Pennell 25-27 part, Hirudo 14-16 part, Semen Platycladi 21-23 part, Rhodobryum roseum Limpr. 21-23 part, Radix Codonopsis 14-16 part, Radix Astragali 14-16 part, Rhizoma Polygonati Odorati 12-15 part, Semen Phaseoli 35-38 part, Fructus Schisandrae Chinensis 12-15 part, Radix Glycyrrhizae 9-10 part.
In a most preferred embodiment of the present invention, the pharmaceutical composition of control left ventricular hypertrophy as mentioned above, wherein said active component is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: 26 parts of Lindernia ruellioides (Colsm.) Pennell, 15 parts of Hirudos, 22 parts of Semen Platycladi, 22 parts of Rhodobryum roseum Limpr.s, 15 parts of Radix Codonopsis, 15 parts of the Radixs Astragali, 13 parts of Rhizoma Polygonati Odorati, 36 parts of Semen Phaseolis, 13 parts of Fructus Schisandrae Chinensis, 9 parts, Radix Glycyrrhizae.
Further preferably, the pharmaceutical composition of above-mentioned control left ventricular hypertrophy, it is oral formulations; Described oral formulations comprises oral liquid, tablet, granule and capsule.
The preparation method that above-mentioned each Chinese medicinal components is prepared into compound preparation of the present invention is: Lindernia ruellioides (Colsm.) Pennell 21-33 part, Hirudo 12-19 part, Semen Platycladi 18-26 part, Rhodobryum roseum Limpr. 18-26 part, Radix Codonopsis 12-19 part, Radix Astragali 12-19 part, Rhizoma Polygonati Odorati 10-18 part, Semen Phaseoli 30-45 part, Fructus Schisandrae Chinensis 10-18 part and Radix Glycyrrhizae 7-13 part of taking recipe quantity, add the water that 10-12 doubly measures, soak 12h-16h, then decoct three times, decoct for the first time 1.5-2h, leach medicinal liquid stand-by; The water that adds for the second time 8-10 doubly to measure, decocts 1-1.5h, leaches medicinal liquid stand-by; The water that adds for the third time 6-8 doubly to measure, decocts 0.8-1h, leaches medicinal liquid stand-by; Merge three times decocting liquid, filter, collect filtrate; Filtrate is concentrated into the thick paste that relative density is 1.25-1.35, low-temperature bake 6-8h, and powder gets dry extract: by dried cream powder: the weight ratio that dextrin is 1: 0.8 adds adjuvant, and common process is granulated, and is sub-packed in capsule after granulate, uses
60co irradiation bomb irradiation sterilization, obtains Chinese medicine preparation of the present invention.
Study discovery by animal experiment, after Oral Administration in Rats Chinese medicine dried cream powder of the present invention, can suppress the formation of rat left ventricular hypertrophy.Therefore, two of object of the present invention is to provide the medical usage of this pharmaceutical composition, specifically, the above-mentioned application in the medicine of preparation control left ventricular hypertrophy by Lindernia ruellioides (Colsm.) Pennell, Hirudo part, Semen Platycladi, Rhodobryum roseum Limpr., Radix Codonopsis, the Radix Astragali, Rhizoma Polygonati Odorati, Semen Phaseoli, Fructus Schisandrae Chinensis and the Radix Glycyrrhizae pharmaceutical composition that totally 10 taste traditional Chinese medicinal material raw materials are prepared from.
The most important advantage of pharmaceutical composition of the present invention is the collaborative formation that suppresses to cause because of long-term Pressure Overload-induced left ventricular hypertrophy.Myocardial hypertrophy extensively sees the various diseases such as hypertensive heart disease, pulmonary heart disease and heart failure.When clinical epidemiology data shows hypertensive patients myocardial hypertrophy, the incidence rate of cardiovascular accident obviously increases, as sudden death, myocardial infarction, arrhythmia, myocardial ischemia, heart failure etc., therefore, prevention myocardial hypertrophy is the problem of attracting attention in current Cardiovarscular.We have proved that by animal experiment attenuates pressure-overload left surgery models rat is after oral Chinese medicine dried cream powder of the present invention, and its left ventricular hypertrophy has obtained suppressing very significantly.
The specific embodiment
The source of the traditional Chinese medicinal material raw materials that the present invention adopts is as follows: Lindernia ruellioides (Colsm.) Pennell is selected the dry herb of goatweed Lindernia ruellioides (Colsm.) Pennell Lindernia ruellioides (Colsm) Pennell..Hirudo is selected from the dry all of Hirudinidae animal Hirudo Whitmania pigra Whitman.Semen Platycladi is selected the kernel of Cupressaceae plant Cacumen Platycladi Biotaorientalis (L.) End1..Rhodobryum roseum Limpr. is selected the dry herb of warm ground of moss Bryaceae rhodobryum spp plant great Ye moss Rhodobryum giganteum (Schwaegr.) Par.Radix Codonopsis is selected the dry root of Campanulaceae Radix Codonopsis Codonopsis pilosula (Franch.) Nannf..The Radix Astragali is selected the dry root of leguminous plant Radix Astagali Astragalus membranaceus (Fisch.) Bge.var.mongholicus (Bge.) Hsiao.Rhizoma Polygonati Odorati is selected the dry rhizome on liliaceous plant (Polygonatum odoratum (Mill.) Druce) jade.Do Semen Phaseoli and select the dry mature seed of leguminous plant Semen Phaseoli Phaseolus calcaratus Roxb..Fructus Schisandrae Chinensis is selected the dry mature fruit of magnoliaceae schisandra Schisandra chinensis (Turcz.) Baill..Radix Glycyrrhizae Preparata is selected the dry root and rhizome into dicotyledon pulse family Leguminosae Radix Glycyrrhizae Glycyrrhiza uralensis Fisch..
Be below specific embodiments of the invention, technical scheme of the present invention is done to further description, but protection scope of the present invention is not limited to these embodiment.Every do not deviate from the change of the present invention design or be equal to substitute include within protection scope of the present invention.
The preparation of embodiment 1 Chinese medicine capsules
Take Lindernia ruellioides (Colsm.) Pennell 26kg, Hirudo 15kg, Semen Platycladi 22kg, Rhodobryum roseum Limpr. 22kg, Radix Codonopsis 15kg, Radix Astragali 15kg, Rhizoma Polygonati Odorati 13kg, Semen Phaseoli 36kg, Fructus Schisandrae Chinensis 13kg and Radix Glycyrrhizae 9kg, merge, add the water of 12 times of amounts, soak 14h, then decoct three times, decoct for the first time 1.5h, leach medicinal liquid stand-by; Add for the second time the water of 9 times of amounts, decoct 1.2h, leach medicinal liquid stand-by; Add for the third time the water of 8 times of amounts, decoct 0.8h, leach medicinal liquid stand-by; Merge three times decocting liquid, filter, collect filtrate; It is 1.3 thick paste that filtrate is concentrated into relative density, low-temperature bake 7h, and powder gets dry extract; By dried cream powder: the weight ratio that dextrin is 1: 0.8 adds adjuvant, common process is granulated, and is sub-packed in capsule after granulate, and every capsules, by the crude drug amount powder charge of 20 grams, is used
60co irradiation bomb irradiation sterilization, obtains capsule preparations.
The preparation of embodiment 2 Chinese medicine capsules
Take Lindernia ruellioides (Colsm.) Pennell 22kg, Hirudo 12kg, Semen Platycladi 20kg, Rhodobryum roseum Limpr. 18kg, Radix Codonopsis 19kg, Radix Astragali 18kg, Rhizoma Polygonati Odorati 18kg, Semen Phaseoli 30kg, Fructus Schisandrae Chinensis 15kg and Radix Glycyrrhizae 13kg, merge, add the water of 11 times of amounts, soak 16h, then decoct three times, decoct for the first time 2h, leach medicinal liquid stand-by; Add for the second time the water of 9 times of amounts, decoct 1.5h, leach medicinal liquid stand-by; Add for the third time the water of 8 times of amounts, decoct 1h, leach medicinal liquid stand-by; Merge three times decocting liquid, filter, collect filtrate; It is 1.3 thick paste that filtrate is concentrated into relative density, low-temperature bake 8h, and powder gets dry extract; By dried cream powder: the weight ratio that dextrin is 1: 0.8 adds adjuvant, common process is granulated, and is sub-packed in capsule after granulate, uses
60co irradiation bomb irradiation sterilization, obtains capsule preparations.
The preparation of embodiment 3 Chinese medicine capsules
Take Lindernia ruellioides (Colsm.) Pennell 30kg, Hirudo 18kg, Semen Platycladi 25kg, Rhodobryum roseum Limpr. 26kg, Radix Codonopsis 12kg, Radix Astragali 15kg, Rhizoma Polygonati Odorati 15kg, Semen Phaseoli 43kg, Fructus Schisandrae Chinensis 18kg and Radix Glycyrrhizae 7kg, merge, add the water of 12 times of amounts, soak 15h, then decoct three times, decoct for the first time 1.5h, leach medicinal liquid stand-by; Add for the second time the water of 8 times of amounts, decoct 1h, leach medicinal liquid stand-by; Add for the third time the water of 8 times of amounts, decoct 0.8h, leach medicinal liquid stand-by; Merge three times decocting liquid, filter, collect filtrate; It is 1.3 thick paste that filtrate is concentrated into relative density, low-temperature bake 7h, and powder gets dry extract; By dried cream powder: the weight ratio that dextrin is 1: 0.8 adds adjuvant, common process is granulated, and is sub-packed in capsule after granulate, uses
60co irradiation bomb irradiation sterilization, obtains capsule preparations.
The treatment research of embodiment 4 Chinese medicines to left ventricular hypertrophy rat model
40 of SD rats, male, weight 200～220g, is divided into following four groups at random: 10 of operation groups, 10 of sham operated rats, 10 of operation+Chinese drug-treated group, 10 of blank groups.
Attenuates pressure-overload left surgery models is made: after 3% pentobarbital sodium 45mg/kg intraperitoneal anesthesia, open abdominal cavity, expose ventral aorta, separate the ventral aorta between the renal artery of left and right, apart from other one No. 6 pins (diameter 0.6mm) of putting in 5mm place, left renal artery opening top, after No. 1 silk thread ligation, extract pin, make attenuates pressure-overload left reach 65%～70%.Postoperative conventional infection 3d close observation reaction of animals.Sham operated rats: at ventral aorta same area threading but not ligation blood vessel, all the other processing are the same.Blank group is not done any processing.
Operation+Chinese drug-treated group rat gives with irrigation stomach device per os the dried cream powder 300mg/kg/d preparing according to the prescription of the embodiment of the present invention 1 and method after surgery, 1 times/day, until within postoperative 16 weeks, stop perfusion, other the three groups normal saline in same time gavage equivalent, four groups of rats all provide normal diet, freely drink water.
Administration is weighed after finishing, and then puts to death rat, by heart excision, removes atriomegaly blood vessel and pericardial tissue, and cool brine is rinsed well, and the ratio that separates left ventricle calculating left ventricle weight in wet base and body weight along interventricular septum is left ventricular hypertrophy index.Result of the test is referring to table 1.
The contrast of the each group of table 1 Left Ventricular Hypertrophy in Rats index
▲with sham operated rats comparison, p < 0.05,
▲ ▲with sham operated rats comparison, p < 0.01.
●with the comparison of operation group, p < 0.05,
● ●with the comparison of operation group, p < 0.01.
Result of the test by table 1 can be found out, left ventricle weight in wet base, body weight and the left ventricular hypertrophy index of operation group and sham operated rats comparing difference all have statistical significance (P < 0.01), this explanation left ventricular hypertrophy model modeling success.In addition, operation+Chinese drug-treated group left ventricle weight in wet base and left ventricular hypertrophy index are lower than operation group (P < < 0.05 or P < < 0.01), and this shows that pharmaceutical composition of the present invention has the effect that rat left ventricular hypertrophy forms that suppresses.
Claims (6)
1. prevent and treat the pharmaceutical composition of left ventricular hypertrophy for one kind, formed by active component and pharmaceutically acceptable auxiliaries, it is characterized in that: described active component is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Lindernia ruellioides (Colsm.) Pennell 21-33 part, Hirudo 12-19 part, Semen Platycladi 18-26 part, Rhodobryum roseum Limpr. 18-26 part, Radix Codonopsis 12-19 part, Radix Astragali 12-19 part, Rhizoma Polygonati Odorati 10-18 part, Semen Phaseoli 30-45 part, Fructus Schisandrae Chinensis 10-18 part, Radix Glycyrrhizae 7-13 part.
2. the pharmaceutical composition of preventing and treating according to claim 1 left ventricular hypertrophy, is characterized in that: described active component is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Lindernia ruellioides (Colsm.) Pennell 25-27 part, Hirudo 14-16 part, Semen Platycladi 21-23 part, Rhodobryum roseum Limpr. 21-23 part, Radix Codonopsis 14-16 part, Radix Astragali 14-16 part, Rhizoma Polygonati Odorati 12-15 part, Semen Phaseoli 35-38 part, Fructus Schisandrae Chinensis 12-15 part, Radix Glycyrrhizae 9-10 part.
3. the pharmaceutical composition of preventing and treating according to claim 2 left ventricular hypertrophy, is characterized in that: described active component is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: 26 parts of Lindernia ruellioides (Colsm.) Pennell, 15 parts of Hirudos, 22 parts of Semen Platycladi, 22 parts of Rhodobryum roseum Limpr.s, 15 parts of Radix Codonopsis, 15 parts of the Radixs Astragali, 13 parts of Rhizoma Polygonati Odorati, 36 parts of Semen Phaseolis, 13 parts of Fructus Schisandrae Chinensis, 9 parts, Radix Glycyrrhizae.
4. according to the pharmaceutical composition of preventing and treating left ventricular hypertrophy described in claim 1 or 2 or 3, it is characterized in that: described pharmaceutical composition is oral formulations.
5. the pharmaceutical composition of preventing and treating according to claim 4 left ventricular hypertrophy, is characterized in that: described oral formulations comprises oral liquid, tablet, granule and capsule.
6. the application of the pharmaceutical composition described in claim 1 or 2 or 3 in the medicine of preparation control left ventricular hypertrophy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410030259.0A CN103768382B (en) | 2014-01-23 | 2014-01-23 | A kind of pharmaceutical composition and application thereof that prevents and treats left ventricular hypertrophy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410030259.0A CN103768382B (en) | 2014-01-23 | 2014-01-23 | A kind of pharmaceutical composition and application thereof that prevents and treats left ventricular hypertrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103768382A true CN103768382A (en) | 2014-05-07 |
| CN103768382B CN103768382B (en) | 2016-05-25 |
Family
ID=50561442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410030259.0A Expired - Fee Related CN103768382B (en) | 2014-01-23 | 2014-01-23 | A kind of pharmaceutical composition and application thereof that prevents and treats left ventricular hypertrophy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103768382B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305844A (en) * | 2001-01-14 | 2001-08-01 | 刘红 | Medicine for treating congestive heart failure |
| CN101181600A (en) * | 2007-11-20 | 2008-05-21 | 王振才 | Traditional chinese medicine composition for curing cardiovascular and cerebrovascular diseases |
-
2014
- 2014-01-23 CN CN201410030259.0A patent/CN103768382B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305844A (en) * | 2001-01-14 | 2001-08-01 | 刘红 | Medicine for treating congestive heart failure |
| CN101181600A (en) * | 2007-11-20 | 2008-05-21 | 王振才 | Traditional chinese medicine composition for curing cardiovascular and cerebrovascular diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103768382B (en) | 2016-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101011522A (en) | Chinese medicinal preparation for treating heart disease | |
| CN103520293A (en) | Oral traditional Chinese medicine for improving and treating constipation | |
| CN106924374A (en) | A kind of composition and preparation method thereof and the application in hypoglycemic and/or reducing blood lipid product is prepared | |
| CN101011562B (en) | Novel formulation of shenqiwendan decoction and production method thereof | |
| CN104095945A (en) | Traditional Chinese medicine composition for treating chronic cardiac failure and oral preparation thereof | |
| CN109512857A (en) | A kind of mannose-Chinese herbal compounds inhibiting tumour growth | |
| CN105287812A (en) | Medicine composition for treating irritable bowel syndromes and application of medicine composition | |
| CN104435567A (en) | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout | |
| CN108283687A (en) | It is a kind of prevention hypertension and heart damage integration of drinking and medicinal herbs Chinese medicine composition and its application | |
| CN103690832A (en) | Traditional Chinese medicinal composition for treating viral myocarditis | |
| CN103768382B (en) | A kind of pharmaceutical composition and application thereof that prevents and treats left ventricular hypertrophy | |
| CN1943755B (en) | A Chinese traditional medicinal composition for treatment of hypertension and its preparation method | |
| CN102205031B (en) | Traditional Chinese medicine for treating male sterility | |
| CN101181582A (en) | Pharmaceutical composition for curing children's urorrhea and preparation method thereof | |
| CN105126034A (en) | Pharmaceutical preparation for treating coronary heart disease | |
| CN104189770A (en) | Pharmaceutical composition for treating tuberculous pleuritis and preparation method thereof | |
| CN104547237A (en) | Traditional Chinese medicinal composition for treating diabetes and method for preparing traditional Chinese medicinal composition | |
| CN110368469A (en) | Join glue stilbene particle drink | |
| CN103372138A (en) | Pharmaceutical composition containing effective components of Shengmai Yin and preparation method of pharmaceutical composition | |
| CN102085313A (en) | Composition with cough-relieving effect | |
| CN104096212A (en) | Traditional Chinese medicine application for treating myocardial infarction and application for same | |
| CN118615345A (en) | Traditional Chinese medicine composition, traditional Chinese medicine extract, traditional Chinese medicine preparation, preparation method and application | |
| CN106421595A (en) | Kidney-tonifying medicine for men | |
| CN103142926B (en) | Pure traditional Chinese medicine preparation for benefiting lung and reducing phlegm | |
| CN104645096A (en) | Traditional Chinese medicine composition for treating rheumatic heart disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ding Hongju Inventor after: Zhou Meili Inventor after: Ye Fuping Inventor after: Gao Yuming Inventor before: Ding Hongju Inventor before: Wang Pingzheng Inventor before: Gao Yuming Inventor before: Han Lingzhi |
|
| COR | Change of bibliographic data | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160525 Termination date: 20170123 |